|Day Low/High||89.26 / 90.17|
|52 Wk Low/High||74.97 / 96.31|
Amgen's rating is lowered at Mizuho but its price target gets raised to $212.
Traders could go long on the eye-care company on strength above $62 risking below $59 with a $72 price target.
It's not really a boom or a bust, says Jim Cramer. The truth is we're muddling along. But it's hard to outrun the bond bears.
The largest impediment to success for firms like TLRY -- which is expected to report a 27 cent loss per share Tuesday night -- remains federal legalization of marijuana across the U.S.
Tilray will look to sustain a sanguine sentiment on cannabis stocks on Tuesday.
Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.
Amgen's patents for Enbrel likely to be protected until 2029.
SAN DIEGO, Aug. 7, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Novartis AG ("Novartis") (NYSE: NVS) for violations of federal securities laws.
These companies already posted strong earnings this season and are not economically sensitive.
The FDA says some data from the testing of Novartis's gene-therapy product Zolgensma was manipulated, but the drug should stay on the market.
The Dow ends up over 300 points on Tuesday, bouncing back one day after its worst session of the year so far.
Jim Cramer says Netflix just went from being an easy-money stock to a hard-money stock. Investors need to know the difference.
Stranger things have happened, but with NFLX's subscriber miss, the stock just became hard money, joining the likes of Johnson & Johnson and CSX Corp.
Swiss drug company sees stock rise following latest earnings report.
Looking for a new retirement option? Target-date funds might be the right fit for you.
Novartis said earlier this week it would make a generic EpiPen to fill the void of Mylan's shortage.
The firm now has a neutral rating on Biogen based on data from a new neurologist survey.
Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?
- Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine
- Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon-14 skipping mutation
- SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2[1,2]
Our preference is to make smaller, incremental buys as the market comes in.
Jim Cramer weighs in on why President Trump cares more about 'beating the Chinese' than the earnings reports that we receive from companies.
Let's review the charts and indicators this morning.
Jim Cramer reviews stocks poised to profit, and those at risk -- until we get some sign of a truce in the trade war.
Jim Cramer is taking a closer look at McDonald's, Kinder Morgan, Intel, Nektar Therapeutics, L Brands, Scientific Games, and more.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.